Press release
XL-protein and Antlia Bioscience Announce Collaboration to Develop Long-acting Peptide Therapy of Chronic Heart Failure using PASylation® Technology
SAN DIEGO, U.S.A., and FREISING, Germany, 15th October, 2020: Antlia Bioscience, Inc., a privately owned biopharmaceutical company located in San Diego, California, and XL-protein GmbH, a privately owned biopharmaceutical company located in Germany, are pleased to announce a Strategic Alliance using XL-protein’s proprietary PASylation® technology for plasma half-life extension to develop a novel, long-acting, peptide therapeutic treatment for chronic heart failure. Brian Johnson, Antlia Bioscience’s CEO commented, “chronic heart failure is a significantly unaddressed medical condition and a major public health concern. XL-protein’s PASylation® technology will allow us to safely and effectively translate our peptide into a meaningful therapeutic option for patients with chronic heart failure. “PASylation® is an excellent biological solution for plasma-half extension of therapeutic peptides, and we believe that PASylation® offers a simpler manufacturing process and superior pharmacological properties,” commented Claus Schalper, CEO of XL-protein. “We are excited to work with Antlia Bioscience to further exploit the potential of our technology and to develop new therapeutic options for the treatment of chronic heart failure.” Financial terms of the agreement have not been disclosed.XL-protein GmbH
Lise-Meitner-Str. 30
85354 Freising - Germany
E-mail: bd@xl-protein.com
About PASylation® Technology
‘PASylation’ involves the genetic fusion or chemical conjugation of a therapeutic protein or pharmaceutically active compound with a conformationally disordered polypeptide of defined sequence comprising the small natural amino acids Pro, Ala, and/or Ser. Due to the biophysical size effect, the typically rapid clearance via renal filtration of the original drug can be retarded by a factor 10-100, depending on the length of the PAS chain. PAS sequences are highly soluble while lacking charges, they are biochemically inert, non-toxic and non-immunogenic, they offer efficient recombinant protein production in a variety of biotechnological host organisms, and they show high stability in blood plasma but are biodegradable by intracellular proteases.
About XL-protein GmbH
XL-protein is a German biotech company commercializing its ground-breaking PASylation® technology, which enables the design of biopharmaceuticals with extended plasma half-life and enhanced action. Based on a strong proprietary technology position, XL-protein focuses at the preclinical as well as clinical development of PASylated proteins in diverse disease areas. XL-protein is engaged in a growing number of partnerships with international pharmaceutical and biotech companies at various levels.
For more information, please visit: www.xl-protein.com
About Antlia Bioscience, Inc.
Antlia Bioscience is a San Diego-based biotech developing groundbreaking peptide-based therapies to treat cardiovascular and metabolic diseases. Using PASylation® and other state-of-the-art techniques, we turn promising peptides into groundbreaking therapies. We are driven to make a profound difference in the treatment of cardiovascular and metabolic diseases and believe that our efforts will result in a paradigm shift in how cardiovascular and metabolic diseases will be treated in the future.
For more information, please visit: www.antliabio.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release XL-protein and Antlia Bioscience Announce Collaboration to Develop Long-acting Peptide Therapy of Chronic Heart Failure using PASylation® Technology here
News-ID: 2161338 • Views: …
More Releases from XL-protein GmbH
XL-protein and DNX Biopharmaceuticals Announce Collaboration to Develop Novel In …
Freising, Germany and San Diego, CA, February 25, 2020 -- XL-protein has extended its existing partnership with DNX Biopharmaceuticals, a biopharmaceutical company developing nonimmunogenic, long-acting therapeutic proteins for the treatment of patients with life-long diseases, to develop novel inflammasome-directed therapeutics for the treatment of diseases linked to inflammation, autoinflammation and oncology. DNX has exercised an option for an exclusive license to research, develop and commercialize a novel antagonist from within…
DNX and XL-protein Announce Collaboration to Develop Novel, Long-Acting Biopharm …
New Half-Life Extension Platform Technology Will Support the Development and Commercialization of Novel Therapeutic Proteins Addressing Unmet Needs in Immunology, Metabolism and Ophthalmology
Irvine, CA and Freising, Germany, June 30, 2015 — DNX Biopharmaceuticals, Inc. (“DNX”) a company with a team of experienced industry professionals with a long and successful track record of developing and manufacturing biopharmaceutical products, and XL-protein GmbH (“XLp”), a leader in protein engineering and modification technologies, today…
YEDA and XL-protein sign business collaboration agreement to commercialize PASyl …
FREISING, GERMANY & REHOVOT, ISRAEL, October 21, 2014:
Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science, Israel, and XL-protein GmbH, Germany, a privately owned biopharmaceutical company, have signed a business collaboration agreement to commercialize a PASylated interferon superagonist – PAS-YNSa8 – which has been jointly developed by scientists at the Weizmann Institute and XL-protein. Under this agreement, YEDA acquires the worldwide exclusive rights…
XL-protein announces publication of key scientific data on its PASylation techno …
FREISING, GERMANY, August 30, 2013 – XL-protein GmbH announced today that key scientific data have been published in the journal Protein Engineering, Design & Selection (2013, Vol. 26, No. 8, pp. 489–501, 2013). The Open Access Publication "PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins" is also available for download at XL-protein's web site (http://www.xl-protein.com/publications.html).
A major limitation of biopharmaceutical proteins is their fast…
More Releases for PAS
New Visiongain Report: Polyarylsulfone (PAS) Market Report 2019-2029
The Polyarylsulfone (PAS) Market is expected to reach $4.1 billion by 2029 after growing at a CAGR of 7.5% over the forecast period from 2019-2029. Excellent characteristics such as elevated heat and chemical resistance encourage the expansion of the range of product implementation in different sectors. Polyarylsulfone is expected to replace polycarbonate and polyamide due to its extremely desirable characteristics in certain sectors such as electrical & electronics, aerospace and…
PAS-X Information Nucleus at B. Braun Irvine
PAS-X Information Nucleus at B. Braun Irvine
US site implements sophisticated multi-level IT architecture with Werum’s PAS-X
Lueneburg, Germany, 12 June 2012 – B. Braun’s facility in Irvine, CA is currently installing a new, highly automated production line, with Werum’s PAS-X as a core component. The line, designed to produce a variety of IV Solution bags for hospitals and clinics, will manufacture the empty bags, fill them, sterilize them, and package them,…
Next Astellas Site will Implement Werum’s PAS-X
Next Astellas Site will Implement Werum’s PAS-X
One of the leading Japanese pharma groups chooses Werum again
Lueneburg, Germany, 24 April 2012 – Astellas Ireland Co. Ltd. (Kerry Plant) has decided to implement Werum´s PAS-X MES at its production facility in Killorglin, County Kerry, Ireland. The MES will introduce efficient and state-of-the-art paperless Electronic Batch Recording functionality supporting compliant, efficient and lean production processes. The MES will be fully integrated with the…
13th PAS-X User Group Meeting in Germany
13th PAS-X User Group Meeting in Germany
Werum Manufacturing IT Conference with record attendance
Lueneburg, Germany, 26 October 2011 – The 13th international PAS-X User Group Meeting took place from 13 to 14 October 2011 in Lueneburg, Germany, with a record attendance. On the invitation of Werum Software & Systems AG, almost 200 pharmaceuticals experts from approximately 20 countries exchanged their thoughts and ideas on the use of the PAS-X production management…
MSD Packaging Lines run with PAS-X
Lueneburg, Germany, August 17, 2010 - MSD deployed PAS-X, the Manufacturing Execution System (MES) by Werum Software & Systems, to run its packaging line operations in Heist-op-den-Berg, Belgium in order to increase the compliance level during packaging operations and subsequently shorten lead times to improve delivery performance. Operations include fully automated blister lines and filling lines, semi-automated packaging lines and manual packaging processes. The project for introducing PAS-X was completed…
Astellas decides to implement Werum's PAS-X
Second largest Japanese pharmaceutical group installs PAS-X at its Dutch production site
Astellas is implementing PAS-X as an EBR (Electronic Batch Recording) at its Dutch production site in Meppel. PAS-X will be set up in Astellas’ pharmaceutical solids production and packaging departments. The project includes PAS-X Business Functions Master Batch Records, Electronic Batch Recording, Weighing & Dispensing, Material Tracking, plus KPI functions. In addition, PAS-X is integrated in Astellas’ overall IT…
